INSERM U-637, Physiopathologie Cardiovasculaire, CHU Arnaud de Villeneuve, Montpellier, France.
Cardiovasc Toxicol. 2010 Jun;10(2):73-86. doi: 10.1007/s12012-010-9064-0.
Cardiac dysfunction occurs during type 1 and type 2 diabetes and results from multiple parameters including glucotoxicity, lipotoxicity, fibrosis and mitochondrial uncoupling. Oxidative stress arises from an imbalance between the production of ROS and the biological system's ability to readily detoxify the reactive intermediates. It is involved in the etiology of diabetes-induced downregulation of heart function. Several studies have reported beneficial effects of a therapy with antioxidant agents, including trace elements and other antioxidants, against the cardiovascular system consequences of diabetes. Antioxidants act through one of three mechanisms to prevent oxidant-induced cell damages. They can reduce the generation of ROS, scavenge ROS, or interfere with ROS-induced alterations. Modulating mitochondrial activity is an important possibility to control ROS production. Hence, the use of PPARalpha agonist to reduce fatty acid oxidation and of trace elements such as zinc and selenium as antioxidants, and physical exercise to induce mitochondrial adaptation, contribute to the prevention of diabetes-induced cardiac dysfunction. The paradigm that inhibiting the overproduction of superoxides and peroxides would prevent cardiac dysfunction in diabetes has been difficult to verify using conventional antioxidants like vitamin E. That led to use of catalytic antioxidants such as SOD/CAT mimetics. Moreover, increases in ROS trigger a cascade of pathological events, including activation of MMPs, PPARs and protein O-GlcNAcation. Multiple tools have been developed to counteract these alterations. Hence, well-tuned, balanced and responsive antioxidant defense systems are vital for proper prevention against diabetic damage. This review aims to summarize our present knowledge on various strategies to control oxidative stress and antagonize cardiac dysfunction during diabetes.
心脏功能障碍发生在 1 型和 2 型糖尿病中,源于多种参数,包括糖毒性、脂毒性、纤维化和线粒体解偶联。氧化应激源于 ROS 的产生与生物系统迅速解毒反应中间体之间的不平衡。它参与了糖尿病引起的心脏功能下调的发病机制。几项研究报告了抗氧化剂治疗的有益效果,包括微量元素和其他抗氧化剂,对抗糖尿病对心血管系统的影响。抗氧化剂通过三种机制之一来防止氧化剂引起的细胞损伤。它们可以减少 ROS 的产生、清除 ROS 或干扰 ROS 引起的改变。调节线粒体活性是控制 ROS 产生的重要可能性。因此,使用 PPARalpha 激动剂来减少脂肪酸氧化和使用锌和硒等微量元素作为抗氧化剂,以及进行体育锻炼以诱导线粒体适应,有助于预防糖尿病引起的心脏功能障碍。使用传统抗氧化剂如维生素 E 难以验证抑制超氧化物和过氧化物的过度产生将预防糖尿病中的心脏功能障碍这一观点。这导致使用 SOD/CAT 模拟物等催化抗氧化剂。此外,ROS 的增加引发一连串的病理事件,包括 MMPs、PPARs 和蛋白质 O-GlcNAcation 的激活。已经开发了多种工具来对抗这些改变。因此,适当的、平衡的和响应性的抗氧化防御系统对于适当预防糖尿病损伤至关重要。这篇综述旨在总结我们目前对控制氧化应激和拮抗糖尿病期间心脏功能障碍的各种策略的了解。